Salveo ODT Dosage/Direction for Use

Olanzapine alone or in combination with fluoxetine is administered once a day, with or without food.
Schizophrenia: See Tables 1 and 2.

Click on icon to see table/diagram/image


Click on icon to see table/diagram/image

Long-term treatment options in adult patients with schizophrenia with remitting first episodes or multiple episodes include either indefinite maintenance therapy or gradual discontinuation of the antipsychotic agent with close follow-up and a plan to reinstitute treatment if symptoms recur.
Discontinuance of antipsychotic therapy should be considered only after a period of at least one year of symptom remission or optimal response while receiving the antipsychotic agent. In patients who have had multiple previous psychotic episodes or two psychotic episodes within five years, indefinite maintenance antipsychotic treatment is recommended.
Bipolar I Disorder (Manic or Mixed Episodes): See Table 3.

Click on icon to see table/diagram/image

Olanzapine in Combination with Fluoxetine: See Tables 4 and 5.

Click on icon to see table/diagram/image


Click on icon to see table/diagram/image

For orodispersible tablets: Olanzapine can be taken without regard to meals. Olanzapine orodispersible tablets should be placed in the mouth, where it will be rapidly dispersed in saliva and can be easily swallowed. Removal of the intact orodispersible tablet from the mouth is difficult. The orodispersible tablet is fragille, thus it should be taken immediately upon opening the blister. Alternatively, it may be dispersed in a full glass of water or other appropriate beverages (orange juice, apple juice, milk, or coffee) immediately before administration.
Olanzapine orodispersible tablet is bioequivalent and has similar rate and extent of absorption with olanzapine coated tablets. It has the same dosage and frequency of administration as olanzapine coated tablets. Olanzapine orodispersible tablets may be used as an alternative to olanzapine coated tablets.
Special Population: Elderly (65 years and older): Recommended Olanzapine Starting Dose: 5 mg/day.
When necessary, increase in dose should be done with caution in these patients.
Patients with Hepatic and/or Renal Impairment: In case of moderate hepatic insufficiency (e.g., cirrhosis, Child-Pugh class A or B), the recommended starting dose should be 5 mg/day.
Further dose adjustments, when indicated, should be conservative in these patients.
Smokers: The starting dose and dose range of olanzapine need not be routinely altered for non-smokers relative to smokers.
Consideration should be given to decreasing the starting dose, when more than one factor is present which might result in slower metabolism (e.g., female gender, geriatric age, non-smoking status). Dose escalation, when indicated, should be conservative in these patients.
Debilitated patients, patients with a predisposition to hypotensive reactions, patients with hepatic impairment, or patients who exhibit a combination of factors that may slow the metabolism of olanzapine or fluoxetine in combination (female gender, geriatric age, non-smoking status), or those patients who may be pharmacodynamically sensitive to olanzapine: Recommended Olanzapine Starting Dose for Schizophrenia: 5 mg; when indicated, dose escalation should be performed with caution in these patients.
Recommended Olanzapine in Combination with Fluoxetine Starting Dose: Olanzapine 2.5 to 5 mg with fluoxetine 20 mg.
Dose modification may be necessary in patients who exhibit a combination of factors that may slow metabolism.
When indicated, dose escalation should be done with caution in these patients.
For children and elderly patients: Olanzapine and fluoxetine in combination have not been systematically studied in patients over 65 years old or in patients below 18 years old.
Or, as prescribed by a physician.